Publications

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013). by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2015; 70 (2): 498-504

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. by Castanheira M, Mills JC, Costello SE, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2015; 59 (6): 3509-3517

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. by Stryjewski ME, Jones RN and Corey GR published in Diagn. Microbiol. Infect. Dis. 2015; 81 (3): 183-188

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. by Penwell WA, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband M, DeJonge BL, Ehmann DE and Miller AA published in Antimicrob. Agents Chemother. 2015; 59 (3): 1680-1689

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. by Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 73-77

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. by Jones RN, Turnidge JD, Moeck G, Arhin FF and Mendes RE published in Antimicrob. Agents Chemother. 2015; 59 (4): 2405-2409,

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2015; 59 (4): 2454-2457

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). by Pfaller MA, Messer SA, Jones RN and Castanheira M. published in J. Antibiot. (Tokyo) 2015; 68 (9): 556-561

MSSA ST398/t034 carrying a plasmid-mediated cfr and erm(B) in Brazil. by Gales AC, Deshpande LM, de Souza AG, Pignatari AC and Mendes RE published in J. Antimicrob. Chemother. 2015; 70 (1): 303-305

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. by Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 283-289

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013). by Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ and Jones RN. published in Antimicrob. Agents Chemother.. 2015; 59 (6): 3656-3659

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. by Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ and Shopsin B published in J. Infect. Dis. 2015; 211 (12): 1862-1874

Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013), Lead author: Farrell DJ, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

In vitro activity of meropenem/RPX7009, a carbapenem/ß-lactamase inhibitor combination against contemporary populations of Enterobacteriaceae and KPC-producing strains, Lead author: Castanheira M, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Tracking Linezolid Antimicrobial Activity and Resistance in North America: Results from LEADER 2013 Program, Lead author: Flamm RK, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Ceftolozane/Tazobactam Activity Tested against Aerobic Gram-negative Organisms Isolated from Intra-abdominal Infections in United States Hospitals (2013), Lead author: Farrell DJ, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Frequency of Occurrence and Antimicrobial Susceptibility of Gram-negative from HCA-UTI in the US: Results from the Program to Assess Ceftolozane/Tazobactam Suscep. (PACTS), Lead author: Farrell DJ, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Antifungal susceptibility patterns of a global collection of fungal isolates and polysorbate-80 effect on the susceptibility of the antifungal classes, Lead author: Castanheira M, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Antimicrobial Activity and Spectrum of Ceftaroline Tested Against Bacterial Isolates Causing Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Differences in Potency and Categorical Agreement between COL and Poly B against 15,377 Strains Collected WW, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Activity of ceftaroline against respiratory tract infection (RTI) pathogens isolated from USA medical centers in 2013, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Activity of Ceftaroline against S. aureus from Patients with Bacteremia in USA Medical Centers (2009-2013), Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

CAZ-AVI activity tested against a large collection of Enterobacteriaceae isolates collected in USA hospitals in the 2011-2013 period, including KPC- and CTX-M-variants, Lead author: Castanheira M, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013), Lead author: Mendes RE, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013), Lead author: Mendes RE, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA

Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Application of New Clinical Breakpoints and Epidemiological Cutoff Values, Lead author: Pfaller MA, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Ceftolozane/Tazobactam Activity Tested against Contemporary (2013) Enterobacteriaceae Strains Causing Infections in United States (USA) Medical Centers, Lead author: Farrell DJ, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Oritavancin Activity against Gram-positive Pathogens Responsible for Documented Infections in US Hospitals (2012-2013), Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Update of the Telavancin Activity in vitro Tested Against a Worldwide Collection of Gram-positive Clinical Isolates (2013), When Applying the Revised Susceptibility Testing Method, Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Activity of the Novel Bacterial Topoisomerase II Inhibitor, GSK2140944, Against Select Gram-positive and Gram-negative Bacteria, Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Multiple Mutations in the Quinolone Resistance Determining Regions (QRDR) Detected Among Fluoroquinolone-Resistant Haemophilus parainfluenzae Collected in the USA, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Ceftaroline Activity Tested against Bacterial Pathogens Frequently Isolated in United States (USA) Medical Centers: Results from 5 Years of AWARE Surveillance Program, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of Ceftolozane/Tazobactam (TOL/TAZ) and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from United States (USA) Medical Centers (2013), Lead author: Farrell DJ, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Serotype Distributions and Susceptibility Profiles of Streptococcus pneumoniae Associated with Noninvasive Infections in Adult Patients in the United States (2009-2012), Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin, Lead author: Jones RN, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Contemporary Arbekacin Activity When Tested against Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia in United States (USA) Hospitals, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Activity of a novel echinocandin biafungin (CD101) tested against most common Candida and Aspergillus species, including echinocandin- and azole-resistant strains, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in USA Medical Centers, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of TD-1607 Tested against Contemporary (2010-2012) Methicillin-Resistant Staphylococcus aureus (MRSA) Strains, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Arbekacin Tested against Well Characterized Multidrug-Resistant (MDR) Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus (MRSA), Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

TD-1607 Tested against Well Characterized Resistant Subsets of Staphylococcus spp., Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

In Vitro Spectrum of Pexiganan Against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms, Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Carbapenemases-producing Enterobacteriaceae in 2013: increasing prevalence of multiple carbapenemases in single isolates, expansion of OXA-48-producers and a new KPC-variant, Lead author: Castanheira M, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Analysis of Vancomycin as a Surrogate Agent for Presumptive Susceptibility Categorization for Telavancin, Lead author: Mendes RE, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

In vitro activity of RX-P873 tested against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., Lead author: Flamm R, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Quality control ranges for performance assessment of a revised broth microdilution susceptibility testing method for telavancin, Lead author: Ross JE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies, Lead author: Farrell DJ, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA